Title

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
SSRIs and Self-harm in Borderline Personality Disorder
  • Phase

    Phase 2
  • Study Type

    Interventional
  • Study Participants

    70
The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young adults with borderline personality disorder who are also currently depressed. Subjects will receive either escitalopram or placebo for eight weeks. During this time subjects will be make weekly visits to see the psychiatrist and record their thoughts and feelings several times each day using an electronic diary.
Study Started
Sep 30
2010
Primary Completion
Nov 30
2014
Study Completion
Nov 30
2014
Results Posted
Jun 14
2019
Last Update
Jun 14
2019

Drug Escitalopram

10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)

  • Other names: Lexapro

Escitalopram Experimental

10-20 mg of escitalopram for eight weeks (10mg for the first 2 weeks, 20mg thereafter)

Placebo Placebo Comparator

Inert placebo (sugar pill) taken daily for eight weeks

Criteria

Inclusion Criteria:

Diagnosis of Borderline Personality Disorder
Current Major Depression

Exclusion Criteria:

Past 2 months SSRI use
Past 6 months non-SSRI antidepressant use
Past 2 months initiation of psychotherapy
Lifetime bipolar disorder, organic disorder, psychotic disorder
Current alcohol or drug dependence
Current severe suicidal / homicidal ideation necessitating immediate medical intervention
Currently pregnancy or nursing
Unable or unwilling to cooperate with study protocol

Summary

Escitalopram

Placebo

All Events

Event Type Organ System Event Term

Self-harm Ideation

Self-harm ideation was measured by electronic diaries (EMA) up to four times a day. Each time a person completed an EMA diary they were asked to rate their urge to hurt themselves on a 5 point scale ( 0 to 4) pad where 0 is not at all, 2 is moderately and 4 is extremely strong.

Escitalopram

Placebo

Depressive Symptoms

Depressive symptoms was assessed via (a) electronic diary (i.e. sum of eight POMS-D items: sad, unhappy, blue, hopeless, discouraged, miserable, helpless and worthless rated using 0-4 scale above) and (b) weekly interview(Hamilton depression rating)

Escitalopram

Placebo

Total

70
Participants

Age, Continuous

28.9
years (Mean)
Standard Deviation: 9.4

Sex: Female, Male

Overall Study

Escitalopram

Placebo

Drop/Withdrawal Reasons

Escitalopram

Placebo